HIGHFDA DRUG
Cipla Lanreotide Acetate Injection Recall: 15,221 Syringes Over Particulate Matter (2026)
Cipla USA, Inc. is recalling 15,221 Lanreotide Acetate Injection syringes nationwide in the United States after detecting particulate matter. The defect is the presence of particulate matter in the injectable solution. Healthcare providers and patients should stop using the product immediately and contact Cipla USA for guidance.
LANREOTIDE ACETATE
Presence of